Published in J Clin Invest on September 01, 2010
Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy. Circulation (2010) 2.15
Barcoding bias in high-throughput multiplex sequencing of miRNA. Genome Res (2011) 2.12
Matricellular proteins in cardiac adaptation and disease. Physiol Rev (2012) 2.01
Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J Clin Invest (2014) 1.82
Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy. Science (2013) 1.75
Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. Circ Res (2011) 1.58
Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol (2011) 1.55
The cell biology of disease: cellular mechanisms of cardiomyopathy. J Cell Biol (2011) 1.54
Epithelial-to-mesenchymal and endothelial-to-mesenchymal transition: from cardiovascular development to disease. Circulation (2012) 1.53
Cardiovascular remodelling in coronary artery disease and heart failure. Lancet (2014) 1.47
The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci (2013) 1.42
Cardiomyocyte-Specific Ablation of Med1 Subunit of the Mediator Complex Causes Lethal Dilated Cardiomyopathy in Mice. PLoS One (2016) 1.41
Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. Am J Physiol Regul Integr Comp Physiol (2011) 1.24
Cardiac Fibrosis: The Fibroblast Awakens. Circ Res (2016) 1.21
Periostin is induced in glomerular injury and expressed de novo in interstitial renal fibrosis. Am J Pathol (2011) 1.19
Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol (2014) 1.16
Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. Curr Pharm Des (2011) 1.16
The adult heart responds to increased workload with physiologic hypertrophy, cardiac stem cell activation, and new myocyte formation. Eur Heart J (2012) 1.16
The Notch pathway controls fibrotic and regenerative repair in the adult heart. Eur Heart J (2012) 1.12
A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science (2016) 1.11
Transforming growth factor beta signaling in adult cardiovascular diseases and repair. Cell Tissue Res (2011) 1.10
Cytokine mediated tissue fibrosis. Biochim Biophys Acta (2012) 1.06
Roles for CCN2 in normal physiological processes. Cell Mol Life Sci (2011) 1.06
Genetics of sudden cardiac death syndromes. Curr Opin Cardiol (2011) 1.02
Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects. Heart Vessels (2013) 1.02
Integrating the myocardial matrix into heart failure recognition and management. Circ Res (2013) 1.00
Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2013) 0.99
Roles of TGF-β signals in endothelial-mesenchymal transition during cardiac fibrosis. Int J Inflam (2011) 0.98
Inhibition of periostin expression protects against the development of renal inflammation and fibrosis. J Am Soc Nephrol (2014) 0.98
Severity of cardiomyopathy associated with adenine nucleotide translocator-1 deficiency correlates with mtDNA haplogroup. Proc Natl Acad Sci U S A (2013) 0.97
A role for partial endothelial-mesenchymal transitions in angiogenesis? Arterioscler Thromb Vasc Biol (2014) 0.97
Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation (2015) 0.96
Adverse fibrosis in the aging heart depends on signaling between myeloid and mesenchymal cells; role of inflammatory fibroblasts. J Mol Cell Cardiol (2013) 0.96
Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice. PLoS One (2011) 0.96
Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy. PLoS One (2012) 0.95
Hypertrophic cardiomyopathy: translating cellular cross talk into therapeutics. J Cell Biol (2012) 0.94
Cardiac fibroblasts: from development to heart failure. J Mol Med (Berl) (2015) 0.93
β-Myosin heavy chain variant Val606Met causes very mild hypertrophic cardiomyopathy in mice, but exacerbates HCM phenotypes in mice carrying other HCM mutations. Circ Res (2014) 0.91
Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail (2013) 0.91
A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin. Circ Heart Fail (2013) 0.91
Aberrant differentiation of fibroblast progenitors contributes to fibrosis in the aged murine heart: role of elevated circulating insulin levels. FASEB J (2013) 0.91
Generation of mice with a conditional allele for the transforming growth factor beta3 gene. Genesis (2012) 0.89
Identification and comparative analyses of myocardial miRNAs involved in the fetal response to maternal obesity. Physiol Genomics (2013) 0.89
Stimulating myocardial regeneration with periostin Peptide in large mammals improves function post-myocardial infarction but increases myocardial fibrosis. PLoS One (2013) 0.89
5'RNA-Seq identifies Fhl1 as a genetic modifier in cardiomyopathy. J Clin Invest (2014) 0.88
Fibroblast growth factor receptor 1 signaling in adult cardiomyocytes increases contractility and results in a hypertrophic cardiomyopathy. PLoS One (2013) 0.87
Heart failure and atrial fibrillation: from basic science to clinical practice. Int J Mol Sci (2015) 0.87
Thoracic aortic disease in two patients with juvenile polyposis syndrome and SMAD4 mutations. Am J Med Genet A (2012) 0.86
Research priorities in sarcomeric cardiomyopathies. Cardiovasc Res (2015) 0.86
Fibrosis-related biomarkers and risk of total and cause-specific mortality: the cardiovascular health study. Am J Epidemiol (2014) 0.86
Transcriptional control of cardiac fibroblast plasticity. J Mol Cell Cardiol (2015) 0.84
Mitral valve disease-morphology and mechanisms. Nat Rev Cardiol (2015) 0.84
Mammalian target of rapamycin is essential for cardiomyocyte survival and heart development in mice. Biochem Biophys Res Commun (2014) 0.84
Intrapericardial delivery of gelfoam enables the targeted delivery of Periostin peptide after myocardial infarction by inducing fibrin clot formation. PLoS One (2012) 0.84
Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail (2017) 0.84
Coronary artery remodeling in a model of left ventricular pressure overload is influenced by platelets and inflammatory cells. PLoS One (2012) 0.83
A role for membrane shape and information processing in cardiac physiology. Pflugers Arch (2014) 0.83
The genetic basis of aortic aneurysm. Cold Spring Harb Perspect Med (2014) 0.82
Hypertrophic cardiomyopathy: a heart in need of an energy bar? Front Physiol (2014) 0.82
Integrated Glycoprotein Immobilization Method for Glycopeptide and Glycan Analysis of Cardiac Hypertrophy. Anal Chem (2015) 0.81
Genetic considerations in hypertrophic cardiomyopathy. Prog Cardiovasc Dis (2012) 0.81
Detection of Cell Proliferation Markers by Immunofluorescence Staining and Microscopy Imaging in Paraffin-Embedded Tissue Sections. Curr Protoc Mol Biol (2016) 0.81
TGFβ-inducible early gene-1 (TIEG1) mutations in hypertrophic cardiomyopathy. J Cell Biochem (2012) 0.80
Roles of collagen and periostin expression by cranial neural crest cells during soft palate development. J Histochem Cytochem (2012) 0.80
p90 ribosomal S6 kinase 3 contributes to cardiac insufficiency in α-tropomyosin Glu180Gly transgenic mice. Am J Physiol Heart Circ Physiol (2013) 0.80
Molecular profiling of dilated cardiomyopathy that progresses to heart failure. JCI Insight (2016) 0.80
Smooth muscle LDL receptor-related protein-1 deletion induces aortic insufficiency and promotes vascular cardiomyopathy in mice. PLoS One (2013) 0.79
Prevalence of aortic dilation in hypertrophic cardiomyopathy. Am J Cardiovasc Dis (2013) 0.79
Identifying gastric cancer related genes using the shortest path algorithm and protein-protein interaction network. Biomed Res Int (2014) 0.79
Stimulation of α1a adrenergic receptors induces cellular proliferation or antiproliferative hypertrophy dependent solely on agonist concentration. PLoS One (2013) 0.79
A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management. Circ Cardiovasc Genet (2013) 0.79
Myosin binding protein C: implications for signal-transduction. J Muscle Res Cell Motil (2011) 0.79
New Role for Interleukin-13 Receptor α1 in Myocardial Homeostasis and Heart Failure. J Am Heart Assoc (2017) 0.78
Searching novel diagnostic markers and targets for therapy of CKD. Kidney Int Suppl (2011) (2014) 0.78
Role of PDGFs/PDGFRs signaling pathway in myocardial fibrosis of DOCA/salt hypertensive rats. Int J Clin Exp Pathol (2013) 0.78
Establishment of a novel murine model of ischemic cardiomyopathy with multiple diffuse coronary lesions. PLoS One (2013) 0.78
Hypertrophic cardiomyopathy: how do mutations lead to disease? Arq Bras Cardiol (2014) 0.78
Towards causally cohesive genotype-phenotype modelling for characterization of the soft-tissue mechanics of the heart in normal and pathological geometries. J R Soc Interface (2015) 0.77
Cardiac steatosis potentiates angiotensin II effects in the heart. Am J Physiol Heart Circ Physiol (2014) 0.77
Sexual dimorphism in activation of placental autophagy in obese women with evidence for fetal programming from a placenta-specific mouse model. Autophagy (2016) 0.77
Targeted Mybpc3 Knock-Out Mice with Cardiac Hypertrophy Exhibit Structural Mitral Valve Abnormalities. J Cardiovasc Dev Dis (2015) 0.77
Assessing the translatability of in vivo cardiotoxicity mechanisms to in vitro models using causal reasoning. BMC Pharmacol Toxicol (2013) 0.77
Downregulation of GSTK1 Is a Common Mechanism Underlying Hypertrophic Cardiomyopathy. Front Pharmacol (2016) 0.77
Kcne2 deletion attenuates acute post-ischaemia/reperfusion myocardial infarction. Cardiovasc Res (2016) 0.77
For whom the cells pull: Hydrogel and micropost devices for measuring traction forces. Methods (2015) 0.77
sFRP2 activates Wnt/β-catenin signaling in cardiac fibroblasts: differential roles in cell growth, energy metabolism, and extracellular matrix remodeling. Am J Physiol Cell Physiol (2016) 0.76
Epicardium-derived fibroblasts in heart development and disease. J Mol Cell Cardiol (2015) 0.76
Familial hypertrophic cardiomyopathy: functional variance among individual cardiomyocytes as a trigger of FHC-phenotype development. Front Physiol (2014) 0.76
Valvular heart diseases in the developing world: developmental biology takes center stage. J Heart Valve Dis (2012) 0.76
Aldosterone promotes cardiac endothelial cell proliferation in vivo. J Am Heart Assoc (2015) 0.76
Right Ventricular Epicardial Fibrosis in Mice With Sternal Segment Dislocation. Vet Pathol (2014) 0.76
Relevance of mouse models of cardiac fibrosis and hypertrophy in cardiac research. Mol Cell Biochem (2016) 0.76
Cardiac Troponin and Tropomyosin: Structural and Cellular Perspectives to Unveil the Hypertrophic Cardiomyopathy Phenotype. Front Physiol (2016) 0.76
Myocardial fibrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson (2014) 0.75
Granule cargo release from bone marrow-derived cells sustains cardiac hypertrophy. Am J Physiol Heart Circ Physiol (2014) 0.75
High sensitivity of late gadolinium enhancement for predicting microscopic myocardial scarring in biopsied specimens in hypertrophic cardiomyopathy. PLoS One (2014) 0.75
Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis. Cell Rep (2016) 0.75
High glucose induces sumoylation of Smad4 via SUMO2/3 in mesangial cells. Biomed Res Int (2014) 0.75
(-)-Epicatechin improves mitochondrial-related protein levels and ameliorates oxidative stress in dystrophic δ-sarcoglycan null mouse striated muscle. FEBS J (2014) 0.75
INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy-a Randomised Intervention Trial with losartan). Glob Cardiol Sci Pract (2015) 0.75
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc (2009) 137.99
DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol (2003) 84.79
Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol (1984) 17.76
Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol (2002) 14.80
Cellular and molecular mechanisms of fibrosis. J Pathol (2008) 14.01
Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication. Science (1982) 10.61
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science (2006) 10.25
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med (2007) 9.51
Identification and characterization of a fibroblast marker: FSP1. J Cell Biol (1995) 6.33
The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell (2001) 5.35
Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med (2007) 5.25
Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science (2007) 5.19
The regulation of TGFbeta signal transduction. Development (2009) 4.59
Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ Res (2007) 4.53
Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther (2009) 4.21
Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med (2007) 3.98
Cardiomyocyte DNA synthesis and binucleation during murine development. Am J Physiol (1996) 3.73
Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science (2003) 3.71
A mouse model of familial hypertrophic cardiomyopathy. Science (1996) 3.69
Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol (1997) 3.67
Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J Cell Biochem (2007) 3.53
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation (2001) 3.21
Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation (2002) 3.20
Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A (2006) 2.85
Circulating transforming growth factor-beta in Marfan syndrome. Circulation (2009) 2.69
Periostin is essential for cardiac healing after acute myocardial infarction. J Exp Med (2008) 2.68
A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia. Nat Genet (2009) 2.67
An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest (2000) 2.56
Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. Circ Res (2000) 2.35
Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation (2003) 2.28
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26
The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation. Nat Med (1999) 1.93
Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail (2009) 1.87
Tissue stiffness, latent TGF-beta1 activation, and mechanical signal transduction: implications for the pathogenesis and treatment of fibrosis. Curr Rheumatol Rep (2009) 1.87
Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay. Am J Physiol Heart Circ Physiol (2007) 1.82
Periostin is expressed within the developing teeth at the sites of epithelial-mesenchymal interaction. Dev Dyn (2004) 1.72
The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol (2009) 1.66
Evaluation of cell proliferation in rat tissues with BrdU, PCNA, Ki-67(MIB-5) immunohistochemistry and in situ hybridization for histone mRNA. J Histochem Cytochem (2003) 1.62
Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation (2006) 1.51
Diastolic dysfunction and its histopathological correlation in obstructive hypertrophic cardiomyopathy in children and adolescents. J Am Soc Echocardiogr (2009) 1.50
Periostin regulates atrioventricular valve maturation. Dev Biol (2008) 1.49
Fibrosis, not cell size, delineates beta-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo. Proc Natl Acad Sci U S A (2006) 1.48
Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol (2004) 1.47
Role of integrin-mediated TGFbeta activation in the pathogenesis of pulmonary fibrosis. Biochem Soc Trans (2009) 1.45
Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease. J Mol Cell Cardiol (2007) 1.42
Influence of myocardial fibrosis on left ventricular diastolic function: noninvasive assessment by cardiac magnetic resonance and echo. Circ Cardiovasc Imaging (2009) 1.39
Altered TGFbeta signaling and cardiovascular manifestations in patients with autosomal recessive cutis laxa type I caused by fibulin-4 deficiency. Eur J Hum Genet (2010) 1.39
Somatic events modify hypertrophic cardiomyopathy pathology and link hypertrophy to arrhythmia. Proc Natl Acad Sci U S A (2005) 1.38
S100A4: a common mediator of epithelial-mesenchymal transition, fibrosis and regeneration in diseases? J Mol Med (Berl) (2008) 1.36
Genetic manipulation of periostin expression in the heart does not affect myocyte content, cell cycle activity, or cardiac repair. Circ Res (2008) 1.35
Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation (2009) 1.30
Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function. Proc Natl Acad Sci U S A (2006) 1.29
Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol (2003) 1.28
Cyclic stretch induces the release of growth promoting factors from cultured neonatal cardiomyocytes and cardiac fibroblasts. Mol Cell Biochem (2000) 1.15
Cardiac myocyte necrosis induced by angiotensin II. Circ Res (1991) 1.13
Cardiology patient pages. Hypertrophic cardiomyopathy. Circulation (2002) 1.13
Bone marrow derived cells are involved in the pathogenesis of cardiac hypertrophy in response to pressure overload. Circulation (2007) 1.10
Monitoring tissue repair and fibrosis from a distance. Circulation (1997) 1.06
Myofilament mechanical performance is enhanced by R403Q myosin in mouse myocardium independent of sex. Am J Physiol Heart Circ Physiol (2008) 1.03
The role of angiotensin II, endothelin-1 and transforming growth factor-beta as autocrine/paracrine mediators of stretch-induced cardiomyocyte hypertrophy. Mol Cell Biochem (2001) 1.02
Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinology (2001) 1.02
Administration of granulocyte colony-stimulating factor after myocardial infarction enhances the recruitment of hematopoietic stem cell-derived myofibroblasts and contributes to cardiac repair. Stem Cells (2007) 1.00
Stretch-induced paracrine hypertrophic stimuli increase TGF-beta1 expression in cardiomyocytes. Mol Cell Biochem (2002) 0.93
Human matrix metalloproteinases: characteristics and pathologic role in altering mesangial homeostasis. Microsc Res Tech (2008) 0.91
Recruitment of new cells into the postnatal heart: potential modification of phenotype by periostin. Ann N Y Acad Sci (2006) 0.91
Histologic characterization of hypertrophic cardiomyopathy with and without myofilament mutations. Am Heart J (2009) 0.83
Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide. Expert Opin Drug Metab Toxicol (2009) 0.79
Cardiovascular magnetic resonance in the evaluation of hypertrophic and infiltrative cardiomyopathies. Heart Fail Clin (2009) 0.79
Hypertrophic cardiomyopathy in China. Am J Cardiol (2007) 0.78
Truncations of titin causing dilated cardiomyopathy. N Engl J Med (2012) 6.07
Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature (2007) 5.82
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science (2007) 5.19
De novo mutations in histone-modifying genes in congenital heart disease. Nature (2013) 5.15
Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab (2005) 4.65
Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes (2006) 4.14
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med (2014) 4.14
De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. Nat Genet (2009) 3.86
A public resource facilitating clinical use of genomes. Proc Natl Acad Sci U S A (2012) 3.72
Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science (2003) 3.71
Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med (2005) 3.71
HIV-infected T cells are migratory vehicles for viral dissemination. Nature (2012) 3.57
Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline. J Card Fail (2009) 3.54
Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J Cell Biochem (2007) 3.53
Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med (2010) 3.42
Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med (2016) 3.40
The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet (2005) 3.36
Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest (2002) 3.33
Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation (2002) 3.20
Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol (2010) 2.96
Genetic causes of human heart failure. J Clin Invest (2005) 2.79
Filter-based hybridization capture of subgenomes enables resequencing and copy-number detection. Nat Methods (2009) 2.71
Endocardial cells form the coronary arteries by angiogenesis through myocardial-endocardial VEGF signaling. Cell (2012) 2.71
Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol (2009) 2.70
Cardiac myosin-binding protein-C phosphorylation and cardiac function. Circ Res (2005) 2.67
Organ printing: computer-aided jet-based 3D tissue engineering. Trends Biotechnol (2003) 2.66
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.53
Cardiac myosin binding protein C phosphorylation is cardioprotective. Proc Natl Acad Sci U S A (2006) 2.46
Organ printing: tissue spheroids as building blocks. Biomaterials (2009) 2.43
Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis. Nat Genet (2012) 2.39
Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. Am J Hum Genet (2011) 2.38
Mutations in the TGF-β repressor SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm. Nat Genet (2012) 2.34
Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation (2003) 2.28
AMP-activated protein kinase in the heart: role during health and disease. Circ Res (2007) 2.27
Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet (2002) 2.27
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26
Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol (2007) 2.18
Transitions in early embryonic atrioventricular valvular function correspond with changes in cushion biomechanics that are predictable by tissue composition. Circ Res (2007) 2.17
A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J Exp Med (2006) 2.15
An in vivo analysis of hematopoietic stem cell potential: hematopoietic origin of cardiac valve interstitial cells. Circ Res (2006) 2.14
Barcoding bias in high-throughput multiplex sequencing of miRNA. Genome Res (2011) 2.12
A molecular pathway including Id2, Tbx5, and Nkx2-5 required for cardiac conduction system development. Cell (2007) 2.12
Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med (2008) 2.12
Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Proc Natl Acad Sci U S A (2008) 2.08
Periostin promotes atrioventricular mesenchyme matrix invasion and remodeling mediated by integrin signaling through Rho/PI 3-kinase. Dev Biol (2006) 2.08
Polycomb repressive complex 2 regulates normal development of the mouse heart. Circ Res (2011) 2.05
Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA (2012) 1.99
Cell and organ printing 2: fusion of cell aggregates in three-dimensional gels. Anat Rec A Discov Mol Cell Evol Biol (2003) 1.98
Epicardium-derived cells in development of annulus fibrosis and persistence of accessory pathways. Circulation (2008) 1.96
Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation (2006) 1.95
Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet (2002) 1.93
Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest (2011) 1.92
Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation (2002) 1.91
Tbx5-dependent rheostatic control of cardiac gene expression and morphogenesis. Dev Biol (2006) 1.91
Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nat Genet (2013) 1.91
Genetics of congenital heart disease: the glass half empty. Circ Res (2013) 1.90
Bone morphogenetic protein-2 can mediate myocardial regulation of atrioventricular cushion mesenchymal cell formation in mice. Dev Biol (2004) 1.89
Construction of normalized RNA-seq libraries for next-generation sequencing using the crab duplex-specific nuclease. Curr Protoc Mol Biol (2011) 1.88
Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol (2003) 1.86
T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci (Lond) (2003) 1.86
Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass grafting. Anesthesiology (2009) 1.85
Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy. J Am Coll Cardiol (2010) 1.83
Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol (2003) 1.81
Nkx2-5 mutation causes anatomic hypoplasia of the cardiac conduction system. J Clin Invest (2004) 1.80
Mutation in the transcriptional coactivator EYA4 causes dilated cardiomyopathy and sensorineural hearing loss. Nat Genet (2005) 1.80
Developmentally programmed gene elimination in Euplotes crassus facilitates a switch in the telomerase catalytic subunit. Cell (2003) 1.79
Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA (2009) 1.75
Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy. Science (2013) 1.75
Contemporary evaluation and management of hypertrophic cardiomyopathy. Circulation (2002) 1.73
T-peak to T-end interval may be a better predictor of high-risk patients with hypertrophic cardiomyopathy associated with a cardiac troponin I mutation than QT dispersion. Clin Cardiol (2002) 1.72
Severe heart failure and early mortality in a double-mutation mouse model of familial hypertrophic cardiomyopathy. Circulation (2008) 1.72